Last reviewed · How we verify

NCT05794997

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol

Completed Results posted Last updated 10 November 2025
What this trial tests

trial testing Propranolol or Carvedilol in Hypertension in 817,337 participants. Completed in 31 December 2023.

Timeline
30 November 2022
Primary endpoint
1 January 2023
31 December 2023

Quick facts

Lead sponsorBrigham and Women's Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment817,337
Start date30 November 2022
Primary completion1 January 2023
Estimated completion31 December 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Brigham and Women's Hospital

Who can join

65 and older, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Time to Dementia Onset Primary · Median follow up times: 1) 298 days (exp), 249 days (ref) 2) 995 days (exp), 981 days (ref) 3) 515 days (exp), 448 days (ref) 4) 307 days (exp), 253 days (ref)

Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.

Analysis 1
GroupValue95% CI
Propranolol or Carvedilol22.9622.48 – 23.45
Atenolol, Bisoprolol or Sotalol19.8419.35 – 20.33
Analysis 2
GroupValue95% CI
Propranolol or Carvedilol26.8226.22 – 27.44
Atenolol, Bisoprolol or Sotalol25.8425.25 – 26.45
Analysis 3
GroupValue95% CI
Propranolol or Carvedilol23.0322.47 – 23.60
Atenolol, Bisoprolol or Sotalol20.2119.64 – 20.79
Analysis 4
GroupValue95% CI
Propranolol or Carvedilol7.216.95 – 7.49
Atenolol, Bisoprolol or Sotalol6.476.20 – 6.75

Sponsor's own description

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Population-Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study.
    Desai RJ, Varma VR, Mahesri M, Lee SB, et al · · 2025 · cited 4× · PMID 39935003 · DOI 10.1002/cpt.3583

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05794997.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing